News & Press

Filter by year:

GeNeuro: financial information and business update for the second quarter 2018

GeNeuro today issued a business update and reported on its cash position and 2018 first-quarter revenues.

A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti‐HERV‐W‐Env monoclonal antibody

François Curtin MD, Corinne Bernard PhD, Sandrine Levet PhD, Hervé Perron PhD, Hervé Porchet MD, Julie Médina PhD, Sam Malpass MSc, David Lloyd PhD, Richard Simpson DM

 

HERV-W-Env involvement in human T1D pathogenesis

S. Levet, J. Joanou, N. Queruel, J.Pierquin & H. Perron

 

GeNeuro Presents New Data Highlighting Role of Human Endogenous Retroviruses in Type 1 Diabetes at American Diabetes Association’s (ADA) 78th Scientific Sessions

Geneva, Switzerland, June 25, 2018 – 7:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis (MS) and type 1 diabetes (T1D), today announced that new data from mouse models confirm the involvement of a pathogenic protein encoded by a member of the human endogenous retroviruses (HERV-W) family, pHERV-W Env, in human T1D pathogenesis. Data were presented at the American Diabetes Association 78th Scientific Session, being held June 22-26, 2018 in Orlando, Florida.

Le Revenu TV - «Servier pourrait licencier un produit de Geneuro»

Le PDG de la biotech franco-suisse a expliqué au Revenu TV pourquoi les résultats mitigés de son GNbAC1 dans une forme de sclérose en plaques n'empêchent pas forcément la poursuite de son développement clinique. Il est aussi revenu sur le parcours boursier de la société, très chahuté en 2017.

 

GeNeuro: financial information and business update for the first quarter 2018

GeNeuro today issued a business update and reported on its cash position and 2018 first-quarter revenues.

GeNeuro Reports 2017 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, 3 April 2018 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS) and Type-1 Diabetes (T1D), today reported its full-year results for the year ended December 31, 2017 and provided a corporate update.

GeNeuro and Servier announce successful 12-month results in neuroprotection for Phase 2b CHANGE-MS Study with GNbAC1 in Multiple Sclerosis

Geneva, Switzerland, and Paris, France, March 26, 2018 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today positive results at 12 months from the CHANGE-MS Phase 2b study of GNbAC1, a novel and promising therapeutic approach for the treatment of multiple sclerosis (MS). The data showed that GNbAC1 administration had a significant, consistent positive impact on key neuroprotection markers known to be linked to disease progression. This is the first time that the benefit of a treatment targeting endogenous retrovirus protein is shown in a clinical trial.

GeNeuro reports cash and revenue at December 31, 2017

Geneva, Switzerland, 12 February 2018 – 7:00am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS) and type-1 diabetes, reports today on its cash and revenue at December 31, 2017.

GeNeuro Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Geneva, Switzerland, 22 February, 2018 – 6:30pm CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that GNbAC1 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune neurological disorder of the peripheral nervous system. In the US, the prevalence rate of CIDP is estimated to be 9 cases per 100,000. Current long-term therapy is often limited by side effects and one-third of patients are refractory to existing treatments.


Start Page      Previous Page      Results 11-20 of 21      Next Page      Last Page